Don't get rid of mercury yet, says AHA (American Heart Association)
This article was originally published in Clinica
Replacing mercury sphygmomanometers with more modern aneroid or electronic instruments is not necessarily a good idea, according to an advisory statement by the American Heart Association's Council for High Blood Pressure Research. The newer types of instrument have a number of drawbacks compared with the "gold standard" mercury gravity sphygmomanometer, the Council says in the journal, Hypertension (February).
You may also be interested in...
Pink Sheet Podcast: US FDA’s Chloroquine EUA And Coronavirus Treatment Accelerator, Novartis Receives No Penalty For Zolgensma Problems
Pink Sheet reporters and editors discuss the effects of the chloroquine emergency use authorization, FDA efforts to speed coronavirus treatment development, and the agency decision against penalizing Novartis over Zolgensma’s data integrity problems.
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.